LIVN

Over the past six months (April 2026 - October 2026), LivaNova's stock (LIVN) has shown a 19.54% increase. In May 2026, strong first-quarter 2026 results, with revenue increasing 14.3%, led to a raised full-year guidance and a significant daily stock increase of 15.1%. In August 2026, the company reported a 10.8% increase in second-quarter 2026 revenue, prompting another raise in its full-year guidance. In March 2026, the U.S. Food and Drug Administration (FDA) approved the aura6000 System for the treatment of moderate to severe Obstructive Sleep Apnea. In September 2026, LivaNova presented at healthcare conferences, reiterating a bullish growth narrative driven by sustained double-digit growth in its epilepsy and cardiopulmonary segments, favorable reimbursement trends, and an expanding pipeline in obstructive sleep apnea. The company is scheduled to announce its third-quarter 2026 results on November 4, 2026. Despite overall positive performance, the stock experienced a -6.79% change over the last month and a -8.01% change over the last three months as of October 9, 2026.